



Date of Deposit: March 28, 2005

Attorney Docket No. VPI/03-103 US
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT & TRADEMARK NO.: 10/800,022

CONFIRMATION NO.: 6802

FILING DATE: MARCH 12, 2004

EXAMINER: NOT YET ASSIGNED

GROUP ART UNIT: 1614

APPLICANTS: VANGOOR, ET AL.

FOR: MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

March 28, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- Copy(ies) of references Citation No(s). **B1-B4 and C1-C3** is/are attached.
- Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- A copy of the International Search Report received in the corresponding PCT Application No. **PCT/US2004/007492** is attached herewith.

(b) No fee is believed due because:

- The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- The Information Disclosure Statement is being concurrently filed with the above-identified application.
- The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

APPLICANTS: VANGOOR, ET AL.

APPLICATION NO.: 10/800,022

- (c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

APPLICANTS: VANGOOR, ET AL.
APPLICATION No.: 10/800,022

- The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,



Nandakumar Govindaswamy
Reg. No. 56,285
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6619/6100
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Mail Stop: Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on _____.

March 28, 2005

Susan Batty - Gunn

Date of Signature



Modified Filing 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/800,022
Filing Date	March 12, 2004
First Named Inventor	Frederick F. VanGoor
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/03-103 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO	00/07996	Chiron Corporation	17 February 2000	
	B2	WO	03/084544	CV Therapeutics, Inc.	16 October 2003	
	B3	DE	41 26 543	Chem. & Pharm. Patent Hold Ltd.	11 February 1993	
	B4	FR	2.104.932	Ferlux	28 April 1972	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Nargund, et al., "Synthesis and Anti-inflammatory Activity of Fluorinated Phenyl Styryl Ketones and N-Phenyl-5-substituted Aryl-3-p-(fluorophenyl) Pyrazolins and Pyrazoles", Journal of Pharm. Sciences, Am. Pharm. Association, Vol 81, No. 9, Pages 892-894, Sept. 1992.
	C2	Nair, et al. "Synthesis & Reactions of 1-(2-Furyl)-3-(substituted-2-hydroxyphenyl)propanediones", Indian J. Chem., Vol. 21, Pages 573-574, 1982
	C3	Database Chemcats, Zelinski Inst. Of Organic Chemistry, Moscow, XP-002288253, 2003

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.